title: Novel immunosuppressive therapies for intestinal and hepatic diseases.
abstract: Recent advances in the understanding of the pathogenesis of immune-mediated hepatic and intestinal diseases have led to major therapeutic advances. The introduction of genetically engineered biologic agents specifically designed to target inflammatory mediators responsible for the perpetuation of chronic inflammatory processes is a novel example. Although corticosteroids remain important as a first-line therapeutic option for active inflammatory bowel disease, approximately one third and one fifth of patients develop steroid dependence and resistance, respectively. From a pediatric perspective, a major advance has thus been the advocation of prolonged immunosuppressive therapy with 6-mercaptopurine or azathioprine for children with inflammatory bowel disease. The introduction of effective steroid-sparing agents for the induction and maintenance of remission is a key management issue. The past year has also witnessed the increased utilization of powerful immunosuppressive agents with rapid onset of action, such as cyclosporine and tacrolimus, in patients resistant to conventional therapies. This review will afford pediatricians a sense of what to expect for the management of hepatic and intestinal disorders with immunosuppression as we advance into the new millenium.
authors.affiliation: Department of Pediatrics, University of Montreal, Quebec, Canada.
authors.forename: M C
authors.initials: MC
authors.lastname: Dubinsky
authors.forename: E G
authors.initials: EG
authors.lastname: Seidman
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use*; D001691:Biological Therapy; D002648:Child; D019693:Hepatitis, Autoimmune / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*
chemical_list: D000963:Antimetabolites; D007166:Immunosuppressive Agents